The Info List - Philip Hampton

--- Advertisement ---

Sir Philip Roy Hampton (born 5 October 1953) is a British businessman, and the current chairman of GlaxoSmithKline. Originally he joined RBS as the deputy chairman on 19 January 2009 and was promoted to chairman on 3 February the same year. He has previously held the chairman role at J Sainsbury
J Sainsbury
plc, parent company of the Sainsbury's chain of supermarkets, and the role of group finance director of a number of blue chip companies including Lloyds Banking Group
Lloyds Banking Group
plc, BT Group
BT Group
plc, BG Group
BG Group
plc, British Gas plc
British Gas plc
and British Steel plc.[1] before becoming the first chairman of UK Financial Investments Limited in 2008, the post he left to join RBS. Biography[edit] Hampton gained an MA in English from Lincoln College, Oxford, in 1975.[2] He joined the accounting firm Coopers & Lybrand the same year, qualified as a chartered accountant in 1978, and then trained as an auditor, working in London and west Africa.[2] He took an MBA from INSEAD
from 1980 to 1981,[2] and returned to join Lazards investment bank for nine years.[3] Working on mergers, acquisitions, business restructurings and capital markets; in 1986 he was seconded to Lazard Freres, New York, and also worked extensively with Lazard
Freres in Paris.[2] Since then Hampton has been:

British Steel plc
British Steel plc
– group finance director from 1990 to 1995; the company were a former client at Lazards British Gas plc
British Gas plc
– group finance director from 1995 to 1997; oversaw double-demerger of Centrica
and then Lattice Group[4] BG Group
BG Group
– group finance director from 1997 to 2000 British Telecom
British Telecom
– group finance director from 2000 to 2002 Lloyds TSB
Lloyds TSB
– group finance director from 2002 to 2004

Hampton was appointed chairman of J Sainsbury
J Sainsbury
plc on 19 July 2004 to replace Sir Peter Davis. His appointment came at a significant time for the retailer; Davis had been forced out as chairman by shareholders due to an extremely generous bonus package despite his dubious performance as chairman and previously as CEO, another shareholder revolt in February 2004 had caused the company to abandon the appointment of Sir Ian Prosser
Ian Prosser
as chairman and Justin King had been appointed chief executive in March 2004. Hampton was described by then BBC Business Editor Jeff Randall as "a well-respected City figure" and a "safe pair of hands". Under the King/Hampton leadership Sainsbury's regained some market share and in June 2006 reported its highest sales increase in four years.[5] In November 2009, David Tyler took over as chairman of Sainsbury's.[6] In the 2004 Budget, Hampton was asked to lead a review of regulatory inspection and enforcement. This review produced the Hampton Report, which led to the Regulatory Enforcement and Sanctions Act 2008. On 3 November 2008, Philip Hampton was appointed as chairman of UK Financial Investments Limited, the firm set up to manage the UK government's shareholding in banks subscribing to its recapitalisation fund. He resigned to join RBS in January 2009. Hampton was knighted in the New Year Honours 2007.[7] RBS Board revolts[edit] In December 2009, the board of RBS warned their major shareholder, the British public, that they would resign unless they were permitted to pay bonuses of £1.5bn to staff in its investment arm.[8] The matter received heavy criticism because it followed a £42bn taxpayer bailout of the banking system. In January 2012, the board of RBS paid a bonus of £963,000 to Stephen Hester, the then chief executive. The Treasury permitted the payment because they feared Mr Hester and much of the board would have quit if the payment had been vetoed by the government as the majority shareholder.[9][10][11][12][13][14][15][16] Hampton made the decision to turn down his £1.4m bonus before the uproar over Stephen Hester's bonus.[17] References[edit]

^ "RBS Board". Rbs.com. Archived from the original on 15 May 2011. Retrieved 25 July 2017.  ^ a b c d "Philip Hampton". HM Treasury. Archived from the original on 10 July 2009. Retrieved 19 January 2009.  ^ Butler, Sarah (20 September 2007). "Business big shot Sir Philip Hampton". The Times. London. Retrieved 22 May 2010.  ^ " Philip Hampton to quit struggling BT within year". The Independent. London. 5 November 2001. Retrieved 22 May 2010.  ^ [1][dead link] ^ HAMPTON, Philip International Who's Who. accessed 3 September 2006. ^ "HAMPTON, Sir Philip (Roy)". Who's Who 2017. Oxford University Press. Retrieved 7 August 2017.  ^ "RBS board could quit over bonuses". BBC News. 3 December 2009. Retrieved 22 May 2010.  ^ "RBS chief Stephen Hester to get £963,000 bonus". Bbc.co.uk. 26 January 2012. Retrieved 25 July 2017 – via www.bbc.co.uk.  ^ "Treasury feared Hester and board would quit". BBC News. 26 January 2012.  ^ Watt, Nicholas; Elliott, Larry; Treanor, Jill (27 January 2012). "Stephen Hester bonus puts David Cameron under pressure". The Guardian. London.  ^ Tyler, Richard (28 January 2012). "Sir Philip Hampton waives £1.4m share award". The Daily Telegraph. London.  ^ "RBS chairman waives share-based bonus". Reuters. 28 January 2012.  ^ Shipman, Tim (27 January 2012). "David Cameron has failed the Borgen test on Hester's bonus". Daily Mail. London.  ^ Metro.co.uk, Metro Web Reporter for (22 January 2012). "Ed Miliband: David Cameron must block Stephen Hester's bonus". Metro.co.uk. Retrieved 25 July 2017.  ^ "Subscribe to read". Financial Times. Retrieved 25 July 2017.  ^ "RBS chairman rejects £1.4m bonus". BBC News. 28 January 2012. 

v t e



Pakistan GlaxoSmithKline
Pharmaceuticals Ltd Stiefel Laboratories ViiV Healthcare (85%)

Predecessors, acquisitions

Allen & Hanburys Beecham Group Block Drug Burroughs Wellcome Glaxo Glaxo Wellcome Human Genome Sciences Recherche et Industrie Thérapeutiques Reliant Pharmaceuticals S. E. Massengill Company SmithKline Beecham Smith, Kline & French




Advair Alli Augmentin Avandia Beconase Boniva Flixonase Hycamtin Lamictal Paxil/Seroxat Serlipet Tagamet Ventolin Wellbutrin/Zyban Zantac … more


Hepatyrix Pandemrix Twinrix


Aquafresh Horlicks Nicoderm Nicorette NiQuitin Sensodyne Tums
… more


BC Powder Geritol Goody's Powder Lucozade Ribena


Board of Directors

Philip Hampton Emma Walmsley Simon Dingemans Roy M. Anderson Manvinder Banga Patrick Vallance Vivienne Cox Lynn Elsenhans Jesse Goodman Judy Lewent Urs Rohner Laurie Glimcher


Thomas Beecham Silas M. Burroughs Mahlon Kline John K. Smith Henry Wellcome Andrew Witty Chris Gent


Canada v. GlaxoSmithKline
Inc. Christopher v. SmithKline Beecham Corp. GlaxoSmithKline
Services Unlimited v Commission United States v. Glaxo Group Ltd. United States v. GlaxoSmithKline


Drug Industry Document Archive GlaxoSmithKline
Prize Side Effects Study 3